FASN
MOLECULAR TARGETfatty acid synthase
FASN (fatty acid synthase) is targeted by 16 compounds in the BiohacksAI evidence corpus, derived from PubMed bioassay data. Each compound is ranked by confidence score (log-normalized assay count × evidence quality).
Compounds Targeting FASN
Ranked by bioassay confidence score (PubChem active assay count × evidence quality).
| # | Compound | Confidence | Active Assays |
|---|---|---|---|
| 1 | epigalocatechin gallate | 5.40 | 220 |
| 2 | omeprazole | 4.64 | 103 |
| 3 | orlistat | 4.23 | 68 |
| 4 | mangostin | 4.14 | 62 |
| 5 | lansoprazole | 4.01 | 54 |
| 6 | pantoprazole | 3.37 | 28 |
| 7 | rabeprazole | 3.18 | 23 |
| 8 | thiolactomycin | 3.09 | 21 |
| 9 | mangostanin | 2.71 | 14 |
| 10 | Cerulenin | 1.79 | 5 |
| 11 | garcinone e | 1.79 | 5 |
| 12 | Dihydroergotoxine | 1.61 | 4 |
| 13 | Hexachlorophene | 1.61 | 4 |
| 14 | egcg | 0.69 | 1 |
| 15 | Oleic Acid | 0.69 | 1 |
| 16 | gedunin | 0.69 | 1 |
About FASN as a Drug Target
FASN (fatty acid synthase) is a well-characterized molecular target in biomedical research. BiohacksAI tracks 16 compounds with documented FASN interaction from PubChem bioassay data, cross-referenced with PubMed clinical evidence. The confidence score reflects the log-normalized count of active PubChem assays, weighted by evidence quality from the BiohacksAI corpus.
FASN inhibitors, activators, and modulators are of interest in research areas including longevity, metabolic health, and neurological function. Each compound profile includes evidence score, RCT count, human study ratio, research velocity, and domain relevance.